Skip to content
Simpler Grants

No. HT942526PRCRPIPA · Defense Health Agency Contracting Activity - DHACA

Open

DoW, Peer Reviewed Cancer, Impact Award

grants.gov listing Full announcement (NOFO)
Dealbreakers No cost share required Audit: not stated Reimbursement-only: not stated
Invitation only
“Invitation to Submit an Application: August 10, 2026” — From the announcement

At a glance

AI summary

The FY26 Peer Reviewed Cancer Research Program Impact Award funds mature cancer research with a near-term impact on clinical cancer care in one of the listed topic areas, and applications must include preliminary data. Eligible applicants include extramural and intramural U.S. Department of Defense organizations, including foreign and domestic, for-profit and nonprofit, and public or private entities; independent investigators at all career levels may serve as PI. The program expects to fund about 30 Impact Award applications at up to $1.5 million each and about 14 Partnering PI Option applications at up to $2.0 million each, for up to 3 years. Cost sharing is not required. Applications must focus on a congressionally directed topic area and a strategic goal, and research on melanoma or cancers originating in the breast, kidney, lung, pancreas, prostate, or ovary is not allowed; rare cancers are also excluded except topic-area cancers that are rare by definition.

AI-generated summary — verify against the announcement

What it funds

  • Science and Technology and other Research and Development
  • Research & Discovery
  • Patients & People with Health Conditions
  • Biomedical & Disease Research
Official description from grants.gov

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Impact Award supports mature research that will have a near-term impact on clinical cancer care in one of the congressionally directed FY26 PRCRP Topic Areas. Applicants must consider how the research project will lead to the advancement of knowledge in cancer research, patient care and/or treatment options in the Military Health System (MHS). Distinctive Features: • Applications must include preliminary data to support feasibility of the study. • Projects must have strong potential to result in a near-term impact in cancer. • The funding mechanism allows clinical trials. • This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit full applications. The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, both applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Who can apply

  • Unrestricted
Geographic restriction None found in the announcement — likely nationwide